All articles tagged with #diagnosis and treatment
A landmark trial of the KRAS-targeting pill daraxonrasib shows pancreatic cancer patients living about twice as long as with standard chemotherapy and with tumors kept in check longer, a potential breakthrough developed by Revolution Medicines that has prompted FDA expanded access while a full review continues.
Thyroid dysfunction can mimic aging, with fatigue and brain fog often dismissed as part of getting older; a 53-year-old woman’s Hashimoto’s diagnosis and improvement on levothyroxine illustrates how treatable thyroid conditions can be when properly evaluated.
Probiotic supplements aren’t proven to help during antibiotic courses and may slow gut recovery; most people’s microbiomes rebound after a course, though some antibiotics can cause lasting changes, and probiotics may help only in high‑risk cases to prevent C. difficile. The author endorses prudent antibiotic use and completing prescribed courses, plus three non‑probiotic strategies to bolster the microbiome during therapy.
A healthy 55-year-old man developed neck and foot stiffness during a two‑week Grand Canyon rafting trip, followed by painful swelling in his shoulders and hands after returning home, leading doctors to misdiagnose his condition as arthritis. Subtle clues eventually revealed a rare syndrome, illustrating how early symptoms can mislead clinicians and delay a correct diagnosis in medicine.
The Washington Post WellBeing piece explains situs inversus, a rare condition in which internal organs are mirrored from their usual positions. Catherine O’Hara was born with it, a condition sometimes manifested as dextrocardia (the heart on the right side). For most people with situs inversus, there are few or no symptoms and the condition is often discovered incidentally, with health implications varying depending on any associated anomalies.
Eosinophilic oesophagitis (EoE), also known as asthma of the oesophagus, is a rare inflammatory condition causing chronic inflammation and stiffness in the oesophagus, leading to food blockages. The condition, driven by excessive immune reaction, has seen a significant rise in cases, with estimates suggesting it now affects approximately 63 in 100,000 people. Diagnosis often takes years, but a new drug called Jorveza has shown marked improvement for patients. Research is ongoing to understand the role of diet and develop easier diagnostic methods.
Philips reported a 6% YoY growth in Q1 FY23 comparable sales to €4.2 billion, driven by the Diagnosis & Treatment businesses and momentum in China. The order book remains strong and is 10% higher than one year ago. The adjusted EBITA margin expanded by 240 bps to 8.6%. Despite a decline in Personal Health businesses, the company recorded double-digit growth in Image-Guided Therapy and Enterprise Diagnostic Informatics and mid-single-digit growth in Diagnostic Imaging. Philips Respironics earmarked €575 million related to the anticipated resolution of the Respironics recall-related economic loss class action in the U.S.